CPT vs STRO · P/E 104, rev $7.1M vs rev $62.0M
Camden Property Trust (CPT) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Camden Property Trust (CPT) is a reit - residential company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CPT revenue for 2024-12-31 was $7.1M. Net income was $170.8M. Revenue was up 106.8% from 2023-12-31 to 2024-12-31. CPT currently screens at market cap $12.11B and trailing P/E 104.0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CPT currently screens at market cap $12.11B and trailing P/E 104.0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CPT and STRO stock pages for the full models.
Not investment advice.